A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Episode 9
CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment
Experts discuss how the safety profiles of various chimeric antigen receptor (CAR) T-cell therapies influence final selection, considering other patient and disease factors that may affect the decision and how the multidisciplinary team communicates on procedural issues, clinical decisions, responsible parties, and next steps in the CAR T-cell therapy process, as well as the routine adoption of tumor burden–guided dosing following patient reevaluation and lymphodepletion.
Video content above is prompted by the following:
When weighing the clinical advantages and adverse event risks of various CAR T-cell therapies, to what degree do the respective safety profiles influence final selection?
- What other patient and/or disease factors may affect that decision?
- How does the multidisciplinary team communicate with its members on procedural issues, clinical decisions, responsible parties, and next steps in the CAR T-cell therapy process?
Following patient reevaluation and lymphodepletion, do you routinely adopt tumor burden–guided dosing of CAR T-cell therapy?